MtoZ Biolabs - Model analysis-of-antibody-drug-development-drug-formati - Antibody Drug Developability/Druglikeness Assessment Service
Antibody drug developability analysis (drugability analysis) is a key strategy used to evaluate the development prospect of candidate antibody drug. This analysis is based on a comprehensive evaluation of multiple aspects of the candidate antibody, including biological activity, pharmacology, pharmacokinetics, safety, and preparation feasibility. Through systematic developability analysis, candidate antibody drug with potential clinical application and commercial value is identified. This strategy is significant for narrowing down the range of candidate drug, reducing development risk, and saving time and costs. Additionally, this analysis strategy also helps predict the drug's performance during clinical trial and market promotion, providing guidance for its clinical transformation and commercial development.
Mass spectrometry (MS) plays a key role in the developability analysis of antibody drugs.
1. Structural Identification of Antibody Drugs
Through MS, the primary structure of antibody drugs can be precisely analyzed. Peptide fingerprint spectra and tandem mass spectrometry (MS/MS) allow for accurate identification of amino acid sequence and detection of key PTMs such as glycosylation and phosphorylation.
2. PTMs Analysis
Many antibody drugs' functionality and stability are related to their PTMs. MS can be used to identify and quantitatively analyze these modifications, thereby understanding the impact of PTMs on drug properties.
3. Analysis of Antibody Assembly and Aggregates
Through MS, the assembly status and formation of aggregates of antibodies can be assessed, which is crucial for evaluating the drug's stability and biological activity.
4. Molecular Weight Analysis
MS can be used to confirm the molecular weight and isotopic patterns of antibody drugs, aiding in ensuring drug quality and consistency.
MtoZ Biolabs, based on Thermo's Obitrap Fusion Lumos mass spectrometer combined with Nano-LC nanoscale chromatography technology, provides antibody drug developability analysis service, offering comprehensive characterization of candidate antibody protein to facilitate the development of novel antibody drug. Free consultation is available.
1. Experimental Procedures
2. Relevant Mass Spectrometry Parameters
3. Detailed Information on Antibody Drug Developability/ Drugability Analysis
4. Mass Spectrometry Images
5. Raw Data
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The name of MtoZ represents “mass to charge ratio” in mass spectrometry analysis, as most of our services are provided based on our well-established mass spectrometry platforms. Our services allow for the rapid and efficient development of research projects, including protein analysis, proteomics, and metabolomics programs.
MtoZ Biolabs is specialized in quantitative multiplexed proteomics and metabolomics applications through the establishment of state-of-the-art mass spectrometry platforms, coupled with high-performance liquid chromatography technology. We are committed to developing efficient, and effective tools for addressing core bioinformatics problems. With a continuing focus on quality, MtoZ Biolabs is well equipped to help you with your needs in proteomics, metabolomics, bioinformatics, and biopharmaceutical research. Our ultimate aim is to provide more rapid, high-throughput, and cost-effective analysis, with exceptional data quality and minimal sample.
Email: marketing@mtoz-biolabs.com